Cargando…
Genetic aberrations of NLRC5 are associated with downregulated MHC‐I antigen presentation and impaired T‐cell immunity in follicular lymphoma
Follicular lymphoma (FL) is the most common indolent non‐Hodgkin lymphoma. Twenty to twenty‐five percent of FL patients have progression of disease within 24 months. These patients may benefit from immunotherapy if intact antigen presentation is present. Molecular mechanisms impairing major histocom...
Autores principales: | Gunawardana, Jay, Lee, Justina N., Bednarska, Karolina, Murigneux, Valentine, de Long, Lilia Merida, Sabdia, Muhammed B., Birch, Simone, Tobin, Joshua W. D., Gandhi, Maher K. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9176136/ https://www.ncbi.nlm.nih.gov/pubmed/35845006 http://dx.doi.org/10.1002/jha2.116 |
Ejemplares similares
-
Clinical features and outcomes of duodenal‐type follicular lymphoma: A single‐center retrospective study
por: Kamijo, Kimimori, et al.
Publicado: (2022) -
Rituximab maintenance significantly reduces early follicular lymphoma progressions in patients treated with frontline R‐CHOP
por: Procházka, Vít, et al.
Publicado: (2020) -
The impact of prior malignancies on the development of second malignancies and survival in follicular lymphoma: A population‐based study
por: Dinnessen, Manette A.W., et al.
Publicado: (2020) -
Phase Ib study of avadomide (CC‐122) in combination with rituximab in patients with relapsed/refractory diffuse large B‐cell lymphoma and follicular lymphoma
por: Nastoupil, Loretta J., et al.
Publicado: (2022) -
An artificial intelligence system applied to recurrent cytogenetic aberrations and genetic progression scores predicts MYC rearrangements in large B‐cell lymphoma
por: García, Rolando, et al.
Publicado: (2022)